Trial reportLasers in surgery and medicine2026
Prospective Evaluation of a Fractional 675-nm Nonablative Laser for Atrophic Acne Scars in Fitzpatrick Skin Types III-IV.
Trial report in Lasers in surgery and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prospective Evaluation of a Fractional 675-nm Nonablative Laser for Atrophic Acne Scars in Fitzpatrick Skin Types III-IV.Lasers in surgery and medicine · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnergy-based treatments for atrophic acne scars (AAS) in darker skin phototypes must balance efficacy with pigmentary safety. While the nonablative 675-nm laser has shown promise with minimal risk of adverse effects, prospective data in Asian populations remain limited. This study evaluated the efficacy, tolerability, and safety of a 675-nm laser for AAS in Fitzpatrick skin types (FSTs) III-IV.
methodsSixteen adults with AAS underwent 3 monthly sessions using sequential Moveo (low-fluence scanning) and Standard (fractional stamping) modes. Outcomes were assessed at baseline and at 1, 3, and 6 months after the final session, including Goodman and Baron quantitative scores (GBQGASGS), Antera® 3D imaging device, patient satisfaction, procedural pain, and adverse events.
resultsGBQGASGS improved by 14.5% at 6 months after the final treatment (19.81 ± 7.31 to 16.94 ± 7.18; p = 0.001), with a 9.7% reduction evident 1 month after the second session (p = 0.017). Antera® 3D analysis demonstrated improvements in skin texture (12.91 ± 4.25 to 11.38 ± 3.97; p = 0.002) and scar volume (2.54 ± 1.33 to 2.04 ± 1.26; p = 0.001). At 6 months, blinded evaluators reported ≥ 25% improvement in 50% of subjects, while 69% of patients reported ≥ 25% improvement. Adverse events were of low incidence and transient in nature, and no serious complications occurred.
conclusionsThe 675-nm laser demonstrated significant and sustained improvements in acne scar metrics in Asian patients with FST III-IV, supporting its role as a pigment-safe, nonablative option for atrophic acne scars in skin of color.
trial registrationThai Clinical Trials Registry: TCTR20250218009.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.